skip to content

CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.